Overview Financials News + Filings Key Docs Ownership
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Alvotech
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/12/2023 |
6-K
| Quarterly results |
10/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
08/01/2023 |
6-K
| Quarterly results |
07/24/2023 |
6-K
| Quarterly results |
07/12/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
06/29/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
06/13/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
06/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/24/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/19/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/05/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
05/04/2023 |
6-K
| Quarterly results |
04/14/2023 |
6-K
| Quarterly results |
03/28/2023 |
6-K
| Quarterly results |
03/01/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
02/10/2023 |
6-K
| Quarterly results |
02/09/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
02/07/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
02/07/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/24/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/23/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/20/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
01/17/2023 |
6-K
| Quarterly results |
01/11/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"6-K",
"Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi ® and Simponi Aria ® REYKJAVIK, ICELAND - Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi ® and Simponi Aria ® . The study will assess the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi in healthy adult subjects. “We are delighted with the progress of the AVT05 development program,” said Joseph McClellan, Chief Scientific Officer. “As we enter our fifth biosimilar candidate into clinical studies, we reaffirm our commitment to improving patient lives by expanding access to affordable biologics.” In..." |
|
01/06/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/22/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/16/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
12/08/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"6-K",
"Announcement",
"Alvotech and STADA Broaden Access to Hukyndra ® adalimumab biosimilar in Europe • Hukyndra ® launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe • Follows initial introduction of Hukyndra in nine countries: Austria, Estonia, Finland, France, Germany, Lithuania, Slovakia, Sweden, and Switzerland • Adalimumab is first product launched through an exclusive strategic partnership announced by Alvotech and STADA in November 2019 covering biosimilar candidates across immunology, oncology, and ophthalmology indications Reykjavik, Iceland; Bad Vilbel, Germany - 7 December 2022 - Alvotech and STADA are contributing to the availability of high-quality biologic treatments in Europe by ro...",
"Announcement" |
|
12/01/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
11/17/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
|
"6-K",
"Alvotech Secures Financing Facilities of Approximately $136 Million",
"Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira ®",
"Summary of New Financing Arrangements",
"Amended and restated Convertible Bond Instrument (Tranche A)",
"Amended and restated Convertible Bond Instrument (Tranche B)",
"Subordinated Loan Agreement by and between Alvotech and Alvogen Lux Holdings S.à r.l.",
"Warrant Agreement by and between Alvotech and Alvogen Lux Holdings S.à r.l.",
"Share Purchase Agreement by and between Alvotech and ATP Holdings ehf.",
"Convertible Bond Instrument by and between Alvotech and the Bondholders named therein",
"Transition Services Agreement between Alvotech and Aztiq Consulting ehf." |
|
11/16/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
10/27/2022 |
6-K
| Quarterly results |
10/19/2022 |
6-K
| Quarterly results |
10/17/2022 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
|
|
|